Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 5Observational 3Expanded_access 1

Sponsor

Cancer Type

CNS 1

Conditions

Recurrence 1Pathologic Processes 1Oligodendroglioma 1Neuroectodermal Tumors 1Neoplasms, Neuroepithelial 1Neoplasms, Nerve Tissue 1Neoplasms, Glandular and Epithelial 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Histologic Type 1Neoplasms 1Glioma 1Disease Attributes 1Astrocytoma 1

Interventions

3-Iodobenzylguanidine 9TIC10 compound 3vorasidenib 1ulixertinib 1tucatinib 1tovorafenib 1rindopepimut 1pembrolizumab 1pegfilgrastim 1paclitaxel-Angiopep-2 conjugate 1omburtamab I-131 1mogamulizumab 1mirdametinib 1gallium maltolate 1fluorodopa F 18 1efineptakin alfa 1carbon-11 methionine 1avapritinib 1Vorinostat 1Vaccination 1Proton Pump Inhibitors 1Potassium Iodide 1OKN 007 1Methionine 1Ketoconazole 1Ipilimumab 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Fenretinide 1Eflornithine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × vorasidenib × CNS × Clear all
NCT05592743 2024-11-05

Vorasidenib Expanded Access Program

Servier

Approved for marketing
CNS

Astrocytoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Oligodendroglioma, Pathologic Processes, Recurrence, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Disease Attributes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡